NK10 inhibitors are a class of chemical compounds that target the NK10 receptor, a protein involved in cellular signaling pathways. These inhibitors are designed to modulate the activity of the NK10 receptor by either blocking or altering its interactions with other molecular partners. NK10, like other receptors of its kind, is primarily found on the surface of certain cell types, where it plays a role in regulating cell communication, growth, and other intracellular processes. The inhibition of NK10 activity can disrupt normal receptor-ligand binding, leading to downstream effects on signaling cascades that regulate a variety of cellular functions.
Structurally, NK10 inhibitors typically contain functional groups capable of interacting with key residues within the NK10 binding pocket. These interactions often rely on hydrophobic forces, hydrogen bonding, or van der Waals interactions to achieve specificity. The molecular design of NK10 inhibitors can vary, with some incorporating rigid, planar cores to fit within the receptor's active site, while others may feature more flexible scaffolds to enhance binding affinity. Modifications to the inhibitor's structure, such as changes to its polar or hydrophobic regions, can significantly affect its ability to bind NK10 and inhibit its function. Advances in chemical design have allowed for the development of highly selective inhibitors, which can be used to study the role of NK10 in various biological systems. These molecules serve as essential tools in understanding the intricacies of receptor-mediated signaling processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $45.00 $111.00 | 61 | |
BCR-ABL kinase inhibitor that can suppress kinase activity, which may be involved in the activation or function of NK10. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
EGFR inhibitor that can interfere with tyrosine kinase signaling, potentially affecting pathways that regulate NK10. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
RAF kinase inhibitor that can inhibit multiple kinases, potentially altering signaling cascades involving NK10. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Receptor tyrosine kinase inhibitor that can affect multiple signaling pathways, and thus could modulate NK10 activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
SRC-family kinase inhibitor that can change kinase signaling, possibly affecting NK10-mediated pathways. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual EGFR and HER2 inhibitor that can disrupt tyrosine kinase signaling, possibly implicating NK10 functionality. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Multi-kinase inhibitor that can affect VEGF signaling and potentially other pathways related to NK10. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
VEGFR inhibitor that can impact signaling pathways, possibly affecting NK10's regulatory functions. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
BCR-ABL inhibitor that can disrupt kinase activity, potentially affecting pathways involving NK10. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
MET, RET, and VEGFR2 inhibitor that can modulate multiple signaling pathways, which may influence NK10's role. | ||||||